首页 正文

KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable

{{output}}
KRAS driver mutations have classically been considered undruggable by direct inhibitors in non-small cell lung cancer (NSCLC) as well as other solid tumors. However, recent advances have led to the first successful direct KRAS inhibitors, beginning with the de... ...